In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.
In a discussion hosted by Dr. Zachary Roberts, Executive Vice President of R&D and Chief Medical Officer at Allogene Therapeutics, leading rheumatologists Dr. Chris Wincup of King’s College Hospital ...
Northwestern Medicine scientists in the laboratory of Stephen Miller, Ph.D., professor emeritus of Microbiology–Immunology, have identified the cellular and molecular mechanisms required for the ...
ABC7 KABC on MSN
UCI Health launches promising clinical trial using CAR T-cell therapy to treat lupus
A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.
Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...
This image shows killer T cells surrounding and attacking a cancer cell. A new atlas developed by researchers at UC San Diego could make it possible to design custom T cells for immunotherapy to ...
Autoimmune diseases share the same core pathology despite their differing clinical manifestations: dysregulated B and T cell activity. B cells contribute to disease progression by secreting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results